Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06098079 · ClinicalTrials.gov registry record · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Phase 4 study of Obesity, sponsored by Currax Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 8,600
- Enrollment target
- 20
- Study locations
NCT06098079 is a Phase 4 study of Obesity that is actively recruiting participants, run by Currax Pharmaceuticals. The registered enrollment target is 8,600 participants, above the 811-participant average among 1,053 other Obesity trials with a reported enrollment target (960% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06098079, a Phase 4 study of Obesity, is actively recruiting participants, sponsored by Currax Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 8,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone-Bupropion (NB) Combination
Study Locations (20)
California
- Velocity Clinical Research, Gardena - Anderson
- Velocity Clinical Research - Chula Vista
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research, San Diego - La Mesa
- Chemidox Clinical Trials Inc. - Lancaster
- Long Beach Clinical Trials - Long Beach
- Velocity Clinical Research - Los Angeles
- Valley Vitality Ventures - Manteca
- National Institute of Clinical Research, Inc. - Pomona
Arizona
- Sun City Research - Glendale
- Cardiovascular Consultants/NextStage Clinical Research - Glendale
- Desert Clinical Research - Mesa
- Velocity Clinical Research, Phoenix - Phoenix
- Fiel Family & Sports Medicine CCT Research - Tempe
- Synexus Clinical Research US; Inc. - Tucson
Alabama
- TrialMed Birmingham (DRS) - Birmingham
- Accel Research Sites Network - Birmingham
- Cullman Clinical Trials - Cullman
- AMR Mobile - Mobile
- Velocity Clinical Research, Mobile - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,600 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2029-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06098079
The ClinicalTrials.gov registry entry for NCT06098079 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 8,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 811-participant average among 1,053 other Obesity trials with a reported enrollment target (960% higher). The listed sponsor is Currax Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06098079 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06098079 about?
NCT06098079 is a clinical study titled "Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)". A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
What is the current status of trial NCT06098079?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 8,600 participants. The study started on 2024-01-03. Estimated completion is 2029-07.
What conditions does trial NCT06098079 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06098079?
The interventions under investigation include: Placebo (DRUG), Naltrexone-Bupropion (NB) Combination (DRUG).
Who is sponsoring clinical trial NCT06098079?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06098079 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
A Study of a Novel Precision Medicine Approach For Obesity
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.